<DOC>
	<DOCNO>NCT00002812</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug give drug different combination may kill cancer cell . PURPOSE : Randomized phase III trial compare effectiveness standard combination chemotherapy treatment intensive combination chemotherapy treat child acute lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare outcomes child high risk acute lymphocytic leukemia ( ALL ) treat postinduction chemotherapy base marrow response day 7 induction therapy : patient rapid early response ( M1/M2 ) , standard v intensified consolidation chemotherapy standard v prolong duration intensification chemotherapy ; patient slow early response , addition doxorubicin v idarubicin cyclophosphamide intensification chemotherapy . II . Decrease incidence avascular necrosis alternate dexamethasone dose patient undergo 2 course delay intensification . III . Assess impact day 7 marrow status outcome patient . IV . Determine prognosis precisely supplement present clinical feature , immunophenotype , ploidy , cytogenetics , early marrow response BAX/BCL-2 ratio , pattern tyrosine kinase activation , leukemic burden follow induction intensification therapy , development high antibody titer E. coli asparaginase . V. Correlate traditional prognostic factor day 7 marrow response , immunophenotype , ploidy , cytogenetics , early marrow response BAX/BCL-2 ratio . OUTLINE : This partially randomize , multicenter study . Patients stratify center . Patients receive one course VPLD regimen comprise vincristine IV daunorubicin IV 15 minute 2 hour day 0 7 , oral prednisone daily day 0-7 , intrathecal cytarabine day 0 , asparaginase pegaspargase intramuscularly day 3 , 5 , 7 . Patients assign 1 2 two postinduction chemotherapy group base bone marrow response day 7 induction . Patients M1/M2 marrow day 7 consider rapid early responder . Patients M3 marrow day 7 consider slow early responder . Group 1 : Rapid early responder Patients receive 2 additional course VPLD induction chemotherapy . Patients randomize 1 4 treatment arm : Arm I : Beginning day 35 induction therapy , patient receive standard Berlin-Frankfurt-Munster ( BFM ) regimen standard delay intensification . Standard BFM patient arm I consist follow : consolidation 5 week cyclophosphamide , cytarabine , mercaptopurine ; interim maintenance 8 week oral methotrexate mercaptopurine ( MTX/MP ) ; delay intensification 7 week consist reinduction vincristine , doxorubicin , oral dexamethasone , asparaginase pegaspargase follow reconsolidation cyclophosphamide , thioguanine , cytarabine . Arm II : Patients receive standard BFM regimen double delay intensification . Patients receive therapy similar arm I , dexamethasone interrupt 1 week delay intensification intensification regimen repeat , separate 8 week interim maintenance course oral MTX/MP . Arm III : Patients receive augment BFM regimen standard delay intensification . Patients receive 9 week consolidation therapy 2 course vincristine pegaspargase alternate arm I consolidation therapy . Vincristine , intravenous methotrexate , pegaspargase ( Capizzi I regimen ) substitute oral MTX/MP interim maintenance regimen . Pegaspargase substitute asparaginase two additional dos vincristine administer delayed intensification . Arm IV : Patients receive augment BFM regimen double delay intensification . Patients receive intensify chemotherapy throughout , combine additional therapy give patient arm II III . Patients receive augmented BFM regimen receive pegaspargase instead asparaginase . Patients CNS disease diagnosis treat arm IV . Patients Philadelphia chromosome positive bone marrow donor nonrandomly assign treatment group slow early responder . All RER patient receive maintenance therapy vincristine/prednisone oral MTX/MP . Intrathecal methotrexate administer periodically throughout protocol treatment . Group 2 : Slow early responder Patients receive augment BFM consolidation therapy Capizzi I interim maintenance identical receive rapid early responder arm IV . Patients randomize receive double delay intensification either idarubicin doxorubicin concurrent cyclophosphamide . All patient receive maintenance therapy vincristine/prednisone oral MTX/MP . Intrathecal MTX administer periodically throughout protocol treatment . Patients CNS disease entry receive craniospinal irradiation daily 5 consecutive day begin day 0 consolidation therapy . All slow early responder diagnosis receive cranial irradiation daily 5 consecutive day consolidation therapy . Patients testicular leukemia diagnosis receive bilateral testicular irradiation daily 5 consecutive day consolidation chemotherapy . Groups 1 2 : Maintenance therapy continue 2 year girls 3 year boys beyond completion consolidation therapy . Patients follow every 4-6 week 1 year , every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : Approximately 1,520 patient accrue study 4 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute lymphocytic leukemia ( ALL ) M3 bone marrow No FAB L3 morphology CNS overt testicular leukemia diagnosis allow High risk status 1021 year old white blood count ( WBC ) 19 year old WBC 50,000/mm3 great PATIENT CHARACTERISTICS : Age : 1 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : No prior therapy ALL except : Emergency therapy blast crisis , superior vena cava syndrome , renal failure due leukemic infiltration Biologic therapy : Not specify Chemotherapy : Intrathecal cytarabine methotrexate allow diagnostic lumbar puncture Induction therapy must begin within 72 hour intrathecal injection Endocrine therapy : At least 12 month since prior prednisone , le 48 hour , reactive airway disease Inhalational steroid allow Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
</DOC>